{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:01:48Z","timestamp":1762272108020},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1983,1]]},"abstract":"<jats:p> Eighteen patients received a continuous intravenous infusion of adriamycin for 14-60 days in a phase I study in which the dose rates were escalated from 2 mg\/sq m\/day to 5 mg\/sq m\/day to establish the optimal dose to be delivered over a 30-day period. The drug was delivered via a tunneled subclavian catheter by a portable infusion pump (Cormed model ML-6) primed to provide a volume of diluted drug of 10 cc\/day. Leukopenia and stomatitis were observed at 4 mg\/sq m\/day doses or greater in 50% of courses. At doses less than 4 mg\/sq m\/day, only 3\/17 courses (18%) were associated with stomatitis. Partial alopecia developed in all patients, but less than 50% of scalp hair was affected. The cumulative dose of continuous infusion adriamycin at 30 days is comparable to the dose delivered by standard bolus intermittent schedules (60-90 mg\/sq m g 21 days), but the adverse drug effects are eliminated or substantially reduced. Cardiac toxicity was assessed in selected patients treated to 450 mg\/sq m or greater by cardiac biopsy and\/or gated pool studies. No histopathologic lesions were noted in 3 patients receiving 450 mg\/sq m or greater. The recommended daily dose rate of adriamycin in this protracted infusion regimen is 3 mg\/sq m\/day. The phase II study of this schedule and dose rate in 38 additional patients (a total of 52 evaluable patients) demonstrated objective responses in 1\/9 soft tissue sarcoma, 1\/3 mesothelioma, 1\/3 hepatoma, and 2\/13 breast cancer. Phase III studies of the protracted continuous infusion schedule for adriamycin are indicated in that clinical activity is demonstrated at a substantial reduction in toxicity. Pharmacologic studies expanding the existing data base are also necessary. <\/jats:p>","DOI":"10.1200\/jco.1983.1.1.24","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T12:48:09Z","timestamp":1487854089000},"page":"24-28","source":"Crossref","is-referenced-by-count":58,"title":["Constant infusion schedule for adriamycin: a phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system."],"prefix":"10.1200","volume":"1","author":[{"given":"J","family":"Lokich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Bothe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Zipoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Sonneborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Philips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1983.1.1.24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T19:53:08Z","timestamp":1653508388000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1983.1.1.24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1983,1]]}},"alternative-id":["10.1200\/JCO.1983.1.1.24"],"URL":"https:\/\/doi.org\/10.1200\/jco.1983.1.1.24","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983,1]]}}}